Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in Fibrostenotic Crohn's Disease-Related Small Bowel Strictures
CTR20213428Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spesolimab in Crohn's disease, sponsored by Boehringer Ingelheim. Started Jan 2022; status: terminated.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20213428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213428.